Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Sep 10;10(9):2249.
doi: 10.3390/biomedicines10092249.

Efficacy and Safety of Combined Brain Stereotactic Radiotherapy and Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer with Brain Metastases

Judith Porte  1 , Caroline Saint-Martin  2 , Thomas Frederic-Moreau  1 , Marie-Ange Massiani  3 , Laurence Bozec  4 , Kim Cao  1 , Pierre Verrelle  1 , Joelle Otz  1 , Eric Jadaud  1 , Mathieu Minsat  1 , Adriana Langer  5 , Nicolas Girard  6 , Gilles Créhange  1 , Arnaud Beddok  1   7
Affiliations

Efficacy and Safety of Combined Brain Stereotactic Radiotherapy and Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer with Brain Metastases

Judith Porte et al. Biomedicines. .

Abstract

Background: To analyze the outcomes of patients with brain metastases (BM) from non-small cell lung cancer (NSCLC) treated with immunotherapy (IT) and stereotactic radiotherapy (SRT) and to study the impact of the sequence between the two modalities.

Methods: The authors reviewed the records of 51 patients with 84 BM from NSCLC treated at Institut Curie with IT and SRT. BM were categorized into three groups: 'SRT before IT', 'concurrent SRT and IT', and 'SRT after IT.' Regional progression-free interval (R-PFI) and overall survival (OS) were estimated using the Kaplan-Meier method.

Results: After a median follow-up from SRT of 22.5 months (2.7-47.3), the 1-year and 2-year OS were 69.7% (95%CI [58.0-83.8]) and 44.0% [30.6-63.2], respectively. Concerning distant intracranial control, the 1-year and 2-year R-PFI were 40.1% [30.1-53.3] and 35.2% [25.1-49.4], respectively. Moreover, one-year R-PFI in 'SRT before IT', 'concurrent SRT and IT', and 'SRT after IT' groups were 24.1%, 49.6%, and 34.2%, respectively (p = 0.094). The type of therapeutic sequence did not appear to impact the risk of brain necrosis.

Conclusions: The concurrent administration of SRT and IT appeared to offer the best locoregional control, without increasing the risk of toxicity, compared to patients treated with SRT before or after IT.

Keywords: brain metastases; immunotherapy; non-small cell lung cancer; stereotactic radiotherapy.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Flow-chart.
Figure 2
Figure 2
Kaplan–Meier Curve of Overall Survival for the 51 patients.
Figure 3
Figure 3
Kaplan–Meier Curve of Regional Progression-Free Interval (A) and Local Progression-Free Interval (B) for 84 metastases.
Figure 4
Figure 4
Kaplan–Meier Curve of Local Progression-Free Interval (A) and Local Progression-Free Interval (B) comparing the ‘concurrent SRT and IT,’ ‘SRT before IT,’ and ‘SRT after IT’ groups for the 84 metastases.
Figure 5
Figure 5
Kaplan–Meier Curve of Local Progression-Free Interval comparing the ‘concurrent SRT and IT,’ ‘SRT before IT,’ and ‘SRT after IT’ groups after excluding the “Durvalumab” group.
See this image and copyright information in PMC

References

    1. Nussbaum E.S., Djalilian H.R., Cho K.H., Hall W.A. Brain Metastases. Histology, Multiplicity, Surgery, and Survival. Cancer. 1996;78:1781–1788. doi: 10.1002/(SICI)1097-0142(19961015)78:8<1781::AID-CNCR19>3.0.CO;2-U. - DOI - PubMed
    1. Soffietti R., Kocher M., Abacioglu U.M., Villa S., Fauchon F., Baumert B.G., Fariselli L., Tzuk-Shina T., Kortmann R.-D., Carrie C., et al. A European Organisation for Research and Treatment of Cancer Phase III Trial of Adjuvant Whole-Brain Radiotherapy versus Observation in Patients with One to Three Brain Metastases from Solid Tumors after Surgical Resection or Radiosurgery: Quality-of-Life Results. J. Clin. Oncol. 2013;31:65–72. doi: 10.1200/JCO.2011.41.0639. - DOI - PubMed
    1. Aoyama H., Tago M., Kato N., Toyoda T., Kenjyo M., Hirota S., Shioura H., Inomata T., Kunieda E., Hayakawa K., et al. Neurocognitive Function of Patients with Brain Metastasis Who Received Either Whole Brain Radiotherapy plus Stereotactic Radiosurgery or Radiosurgery Alone. Int. J. Radiat. Oncol. Biol. Phys. 2007;68:1388–1395. doi: 10.1016/j.ijrobp.2007.03.048. - DOI - PubMed
    1. Chang E.L., Wefel J.S., Hess K.R., Allen P.K., Lang F.F., Kornguth D.G., Arbuckle R.B., Swint J.M., Shiu A.S., Maor M.H., et al. Neurocognition in Patients with Brain Metastases Treated with Radiosurgery or Radiosurgery plus Whole-Brain Irradiation: A Randomised Controlled Trial. Lancet Oncol. 2009;10:1037–1044. doi: 10.1016/S1470-2045(09)70263-3. - DOI - PubMed
    1. Brown P.D., Jaeckle K., Ballman K.V., Farace E., Cerhan J.H., Anderson S.K., Carrero X.W., Barker F.G., Deming R., Burri S.H., et al. Effect of Radiosurgery Alone vs Radiosurgery with Whole Brain Radiation Therapy on Cognitive Function in Patients with 1 to 3 Brain Metastases: A Randomized Clinical Trial. JAMA. 2016;316:401–409. doi: 10.1001/jama.2016.9839. - DOI - PMC - PubMed

LinkOut - more resources